HAE - Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference

Haemonetics Corporation (NYSE: HAE) has announced that its President and CEO, Chris Simon, will participate in a fireside chat during the Goldman Sachs 46th Annual Global Healthcare Conference. The event is scheduled for June 9, 2025, at 8:40 a.m. ET, giving investors a unique opportunity to hear insights from the company’s leadership.

The conference will include a live webcast accessible through Haemonetics' Investor Relations page, allowing a broader audience to engage with the discussion. For those unable to tune in live, a recorded version of the chat will be available for replay 12 hours after the event and will remain accessible for 90 days.

Haemonetics is a distinguished global medical technology firm focused on enhancing healthcare quality, effectiveness, and efficiency. The company is recognized for its innovative solutions that cater to critical medical requirements. Its portfolio includes advanced hospital technologies aimed at improving patient care, as well as comprehensive plasma collection technologies that optimize operations for plasma centers. Additionally, Haemonetics offers products designed to aid blood centers in the collection of essential blood components.

As the healthcare sector continues to evolve, Haemonetics positions itself at the forefront by addressing pressing medical needs through its state-of-the-art technologies. Stakeholders looking for detailed updates on the company’s strategies and developments are encouraged to follow the upcoming fireside chat and utilize the investor resources available on Haemonetics' website.

For investor relations, contacts include Olga Guyette, Vice President-Investor Relations & Treasury, and David Trenk, Manager-Investor Relations, both of whom can provide further information regarding the company’s initiatives and performance.

As Haemonetics Corporation prepares to present at the Goldman Sachs 46th Annual Global Healthcare Conference, investors should closely analyze the company’s developmental strategies and market positioning within the healthcare technology sector. The ongoing focus on innovative blood management solutions, plasma collection technologies, and enhancements to hospital efficiencies places Haemonetics in a promising position within the rapidly evolving medical landscape.

Haemonetics' commitment to improving patient outcomes through advanced technology is noteworthy, particularly as demand for efficient healthcare solutions continues to grow. The company's diverse product portfolio, which includes blood component collection and processing systems, caters to increasing healthcare needs driven by demographic changes, especially within aging populations. This aligns Haemonetics with broader industry trends toward automated solutions that enhance operational efficiency and effectiveness in healthcare delivery.

As potential investors asses Haemonetics’ market performance, key metrics to monitor include revenue growth trends, profit margins, and developments in research and innovation that can further expand their product offerings. The expected live webcast of the fireside chat offers a valuable opportunity for investors to gauge the company’s strategic direction directly from leadership. Attention to Chris Simon's insights may highlight upcoming product launches, market expansion strategies, or partnerships that could significantly impact future revenue streams.

Investors should also consider external macroeconomic factors, including healthcare policies and reimbursement frameworks, which can affect Haemonetics' operational environment. Given the company’s strong fundamentals, forward-looking statements made during the conference could signal buy or sell considerations depending on market sentiment and strategic developments shared.

In summary, with its innovative approach and dedication to enhancing healthcare solutions, Haemonetics remains a compelling investment candidate, particularly if favorable insights emerge from their upcoming presentation.